Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The company will market it under the brand name Molflu
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Subscribe To Our Newsletter & Stay Updated
